NCCN VERSION 2 2015

143 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-68
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-
2795. Available at: .
17. Hammond ME. ASCO-CAP guidelines for breast predictive factor
testing: an update. Appl Immunohistochem Mol Morphol 2011;19:499-
500. Available at: .
18. Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of
the status of Her-2/neu protein and oncogene in breast cancer
specimens: comparison of immunohistochemistry assay with
fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374-
381. Available at: .
19. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2
gene amplification by fluorescence in situ hybridization and
concordance with the clinical trials immunohistochemical assay in
women with metastatic breast cancer evaluated for treatment with
trastuzumab. Breast Cancer Res Treat 2005;93:3-11. Available at:
.
20. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of
HER2 testing--National Surgical Adjuvant Breast and Bowel Project
experience. J Natl Cancer Inst 2002;94:852-854. Available at:
.
21. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local,
central, and reference laboratories in specimens from the North Central
Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol
2006;24:3032-3038. Available at:
.
22. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical
laboratory testing of eligibility for trastuzumab therapy: apparent
immunohistochemical false-positives do not get the message. J Clin
Oncol 2001;19:2714-2721. Available at:
.
23. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of
HER-2 as a molecular target: an assessment of accuracy and
reproducibility of laboratory testing in large, prospective, randomized
clinical trials. Clin Cancer Res 2005;11:6598-6607. Available at:
.
24. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for
human epidermal growth factor receptor 2 testing in breast cancer:
American Society of Clinical Oncology/College of American Pathologists
clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
Available at: .
25. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for
Human Epidermal Growth Factor Receptor 2 testing in breast cancer:
American Society of Clinical Oncology/College of American Pathologists
Clinical Practice Guideline update. Arch Pathol Lab Med 2014;138:241-
256. Available at:
26. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men.
Ann Intern Med 2002;137:678-687. Available at:
.
27. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of
anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235-237.
Available at: .
28. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol
1991;15:209-221. Available at:
29. Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver
reproducibility in the diagnosis of ductal proliferative breast lesions
using standardized criteria. Am J Surg Pathol 1992;16:1133-1143.
Available at:
30. Renshaw AA, Derhagopian RP, Martinez P, Gould EW. Lobular
neoplasia in breast core needle biopsy specimens is associated with a
low risk of ductal carcinoma in situ or invasive carcinoma on